Vilazodone

• Major Depressive Disorder
• Depression
• Mood Disorders

Vilazodone, sold as Viibryd, is a once-daily oral antidepressant that combines selective serotonin reuptake inhibition (SSRI activity) with partial agonism at the 5-HT1A receptor — a dual mechanism conceptually similar to combining an SSRI with buspirone. It is FDA-approved for major depressive disorder in adults and is sometimes preferred over conventional SSRIs for patients who are sensitive to sexual side effects or weight gain, although head-to-head efficacy data versus generic SSRIs are limited and cost differences are significant. The medication is given once daily with food and requires a structured 14-day titration to reach the target dose, an important counseling point for patients and clinicians.

Mechanism of Action

Vilazodone has two complementary serotonergic actions. First, it blocks the serotonin transporter (SERT), increasing synaptic serotonin in the same way as conventional SSRIs like sertraline, escitalopram, paroxetine, and fluoxetine. Second, it acts as a partial agonist at presynaptic and postsynaptic 5-HT1A receptors. Presynaptic 5-HT1A activation typically suppresses serotonin release through a negative-feedback autoreceptor, but partial agonism allows some signaling while desensitizing the autoreceptor more rapidly than SSRIs alone — a mechanism hypothesized to shorten the latency to clinical response, although this has not been consistently demonstrated in head-to-head trials. Postsynaptic 5-HT1A activation contributes to anxiolytic and possibly pro-cognitive effects and may partially counterbalance the sexual side effects associated with serotonergic agents, although vilazodone can still produce sexual dysfunction. The drug is metabolized primarily by CYP3A4, with secondary contributions from CYP2C19 and CYP2D6, which underlies most clinically significant drug interactions. The NIMH depression overview provides patient-friendly background on antidepressant mechanisms and treatment expectations.

Clinical Use

For major depression, the choice among first-line antidepressants is largely driven by side effect profile, drug interactions, prior personal or family response, and patient preference per APA practice guidelines. Generic SSRIs and SNRIs (duloxetine, venlafaxine, desvenlafaxine) are typical starting agents, with bupropion and mirtazapine common alternatives based on side effect priorities. Vilazodone may be selected when minimizing sexual dysfunction, weight gain, or sedation matters, or in patients with significant comorbid generalized-anxiety-disorder-gad, where the 5-HT1A agonist component theoretically helps, though the evidence base is modest. Patients who have not responded to two SSRI trials should be considered for switching class (SNRI, bupropion, mirtazapine), augmenting with aripiprazole, brexpiprazole, or another atypical antipsychotic, or referral to psychiatry for consideration of newer options including esketamine. Always evaluate for bipolar disorder before initiating an antidepressant, as monotherapy can precipitate mania. Address contributing factors — sleep, alcohol, substance use, thyroid disease, anemia, vitamin D deficiency — in parallel. The companion article st-pete-mental-health-anxiety-guide covers integrated care strategies.

How to Take It

Take one tablet by mouth once daily with food — food roughly doubles bioavailability and is essential for adequate exposure; taking the dose on an empty stomach can reduce blood levels by up to 50% and undermine efficacy. Use a structured 14-day titration: 10 mg daily for seven days, then 20 mg daily for seven days, then 40 mg daily as the target dose. This stepwise increase markedly reduces nausea and diarrhea, the most common reasons patients abandon therapy in the first weeks. Pick a consistent meal — many patients find dinner works well, since taking it earlier in the day with breakfast or lunch occasionally produces transient nausea or activation. If you miss a dose, take it with food when remembered the same day; if it is already the next day, skip and resume the schedule rather than doubling. Do not stop abruptly after sustained use; taper over 1–2 weeks to reduce discontinuation symptoms (dizziness, irritability, flu-like sensations, electric-shock paresthesias). Allow 4–6 weeks at the target dose before judging response — partial response often becomes full response with continued treatment.

Monitoring and Follow-Up

No routine laboratory monitoring is required for vilazodone itself. At 2-week and 6-week follow-ups, screen for response and remission with PHQ-9 (depression) and GAD-7 (anxiety) instruments and assess emergence of suicidal ideation, especially in patients younger than 25 — a class-wide black box warning applies. Check sodium in older adults at baseline and after 1–3 months because SSRIs and SSRI-like agents can cause SIADH and hyponatremia, sometimes presenting as confusion, falls, or new seizures. Review bleeding risk in patients on antiplatelets, anticoagulants, or NSAIDs and consider acid suppression if combining with chronic NSAIDs. Our understanding-blood-work-lab-panels overview can help patients understand sodium and other relevant labs. Reassess for emergent mania, agitation, akathisia, new sexual dysfunction, sleep change, weight change, and gastrointestinal symptoms at each visit. Once stable, follow-up every 3 months for the first year and at least biannually thereafter is reasonable, with continued discussion of treatment duration — most patients should continue for at least 6–12 months after first remission and longer for recurrent episodes.

Special Populations

No dose adjustment is required for hepatic impairment or for mild-to-moderate renal impairment; data are limited in severe renal disease. Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir) require limiting the dose to 20 mg daily; strong inducers (carbamazepine, rifampin, phenytoin) may require an upward dose adjustment up to 80 mg daily based on response. Pregnancy: third-trimester SSRI exposure has been associated with neonatal adaptation syndrome and rare persistent pulmonary hypertension of the newborn; the decision to continue is shared and should weigh the substantial risks of untreated maternal depression, including impaired prenatal care, postpartum depression, and effects on fetal and infant development. Lactation: vilazodone passes into breast milk in low amounts; sertraline is generally preferred during lactation when feasible because of more extensive safety data. Pediatric efficacy and safety have not been established. Older adults do not require dose adjustment but often tolerate slower titration with smaller increments. Patients with bipolar disorder, recent myocardial infarction, or significant cardiovascular disease warrant individualized assessment.

Drug Interactions and Practical Counseling

The most important interactions involve serotonergic agents and CYP3A4. Concurrent MAO inhibitors are contraindicated; allow 14 days between agents. Linezolid and intravenous methylene blue can precipitate serotonin syndrome and are likewise contraindicated unless the situation is life-threatening and managed with monitoring. Triptans for migraine including sumatriptan, tramadol, fentanyl, dextromethorphan, St. John's wort, and other antidepressants can additively elevate serotonin tone — symptoms include hyperthermia, muscle rigidity, clonus, agitation, autonomic instability, and diarrhea. Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir) cap the daily dose at 20 mg. NSAIDs, antiplatelets, and anticoagulants raise bleeding risk; consider gastroprotection with chronic NSAID use. Alcohol is best minimized. Patients with diabetes may notice glucose fluctuations early in treatment.

Course of Treatment and Discontinuation Planning

Antidepressants are not lifelong commitments for most patients, but neither are they short-term tools. After a first episode of major depression, continuing treatment for at least 6–12 months after remission reduces relapse risk substantially. Patients with two or more prior episodes, severe episodes, family history of depression, or persistent residual symptoms benefit from longer maintenance — often years. When discontinuation is appropriate, taper slowly over weeks to months to reduce discontinuation symptoms; cross-tapering with another agent may be needed for those who must switch. Reassess thyroid function, vitamin levels, sleep, and substance use periodically, as new contributors can emerge. Psychotherapy — particularly cognitive behavioral therapy and behavioral activation — paired with medication produces the most durable results. The SAMHSA helpline (1-800-662-HELP) provides 24/7 confidential support and treatment referrals.

When to Contact Your Doctor

Call for new or worsening suicidal thoughts, agitation or restlessness, mania (decreased need for sleep, racing thoughts, impulsive behavior, grandiosity), unusual bleeding or bruising, severe nausea or vomiting that prevents eating or taking medications, signs of low sodium (headache, confusion, weakness, falls), or symptoms of serotonin syndrome (high fever, muscle rigidity, rapid heart rate, severe diarrhea, agitation, tremor), particularly when starting other serotonergic medications such as triptans for migraine, tramadol, linezolid, or recreational substances like MDMA. New seizure activity or severe rash also warrant prompt evaluation.

Depression treatment is a partnership between medication, therapy, and lifestyle changes that include sleep, exercise, social connection, and management of contributing physical conditions. To find an antidepressant strategy that fits your overall health and goals, contact us or schedule a visit.